Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Large Growth in Short Interest

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 10,200 shares, a growth of 161.5% from the March 31st total of 3,900 shares. Currently, 1.7% of the shares of the company are short sold. Based on an average trading volume of 10,900 shares, the days-to-cover ratio is presently 0.9 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Titan Pharmaceuticals in a research note on Tuesday. They set a “sell” rating on the stock.

Titan Pharmaceuticals Trading Up 1.7 %

Titan Pharmaceuticals stock traded up $0.12 during mid-day trading on Friday, hitting $7.09. The stock had a trading volume of 10,649 shares, compared to its average volume of 5,128. The firm has a market capitalization of $6.45 million, a P/E ratio of -0.86 and a beta of 1.33. The firm’s 50 day moving average is $7.36 and its 200 day moving average is $7.15. Titan Pharmaceuticals has a one year low of $5.00 and a one year high of $16.60.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.